US Smart Insulin Pens Market Industry Trends and Forecast to 2034: Segmented by (Type, Connectivity, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
US · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$65.6 MnPlaceholder estimate
Estimate 2025$76.2 Mn42.1% of the global market
Projected 2034$291.9 Mn 283.3%Adds $215.7 Mn over 9 forecast years
CAGR 2025–203416.1%Faster than 93% of 173 Medical Devices markets here
Key players5
US is 42.07% of the global market.
In North America, the largest is US (this report) at $76.2 Mn.
4 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The US Smart Insulin Pens Market Analysis Executive Summary
Smart insulin pens record each dose and send it to an app, helping people with diabetes track insulin and avoid missed or double doses.
Key segments of the smart Insulin Pens market include type (Reusable Smart Pens and Smart Pen Caps and Attachments) and connectivity (Bluetooth and NFC).
US Smart Insulin Pens market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
US Smart Insulin Pens Market Dynamics
Market Growth Drivers
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the smart Insulin Pens market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Opportunity
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the smart Insulin Pens market, especially in fast-growing emerging economies.
Market Restraints
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the smart Insulin Pens market. Long-term safety data and lifestyle support are still needed for many patients.
Competitive Landscape for Smart Insulin Pens Market in US
The smart Insulin Pens market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Smart Insulin Pens Market in US
Smart Insulin Pens in the US: rules, payment and research
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA).[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2] ClinicalTrials.gov lists 4 studies on Smart Insulin Pens that are recruiting, active or about to start in the US.[3] Diabetes (adults): 12.5% of adults in 2022, the latest WHO figure for the US.[4]
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how smart Insulin Pens products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in US.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Type
4.2 By Connectivity
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Novo Nordisk
7.2 Medtronic
7.3 Bigfoot Biomedical
7.4 Sanofi
7.5 Biocorp
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The smart Insulin Pens market can be segmented based on various criteria, including type, connectivity and end user. Here's a breakdown of the market segmentation
How big is the Smart Insulin Pens market in the US?
Placeholder estimate: about $76.2 Mn in 2025, rising to about $291.9 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Smart Insulin Pens market in the US growing?
Placeholder estimate: about 16.1% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Smart Insulin Pens market report cover?
The report splits the market by type (Reusable Smart Pens, Smart Pen Caps and Attachments), connectivity (Bluetooth, NFC) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Smart Insulin Pens market?
Key players include Novo Nordisk A/S, Medtronic, Bigfoot Biomedical, Sanofi and Biocorp.
What is driving the Smart Insulin Pens market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the smart Insulin Pens market.
Who regulates Smart Insulin Pens in the US?
The FDA clears or approves medical devices by risk class, through 510(k) clearance, De Novo classification or premarket approval (PMA). Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on Smart Insulin Pens are running in the US?
4 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
What does WHO report for the US?
Diabetes (adults): 12.5% of adults in 2022, the latest WHO figure. Source: WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 15 Nov 2026.
How many people in the US are 65 or older?
18.4% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 16 Nov 2026.